Ekso Bionics Holdings, Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Income Taxes

Income Taxes

12 Months Ended

Dec. 31, 2015

15. Income Taxes

The domestic and foreign components of pre-tax loss for the years ended December 31, 2015, 2014 and 2013 were as follows:

	Years Ended December 31,
	2015		2014		2013
Domestic	$	(19,918)	$	(33,750)	$	(11,928)
Foreign		328		113		65
Loss before income taxes	$	(19,590)	$	(33,637)	$	(11,863)

The Company had no current or deferred federal and state income tax expense or benefit for the years ended December 31, 2015, 2014 and 2013 because the Company generated net operating losses, and currently management does not believe it is more likely than not that the net operating losses will be realized. The Company’s non-U.S. tax obligation is primarily for business activities conducted through the United Kingdom for which taxes included in other expense (net) for the years ended December 31, 2015, 2014 and 2013 were immaterial and accordingly, such amounts were excluded from the following tables.

Income tax expense (benefit) for the years ended December 31, 2015, 2014 and 2013 differed from the amounts computed by applying the statutory federal income tax rate of 34% to pretax income (loss) as a result of the following:

	Years Ended December 31,
	2015			2014			2013

Federal tax at statutory rate		34.0	%		34.0	%		34.0	%
State tax, net of federal tax effect		-			1.5			5.8
R&D credit		0.5			0.3			-
Change in valuation allowance		(38.4)			(18.9)			(40.1)
Non- deductible expenses		(1.0)			(.2)			(3.6)
Unrealized (gain) loss on warrant		4.3
Foreign		0.5			(0.1)			(0.1)
Other		0.1			0.1			1.6
Total tax expense		-	%		-	%		-	%

The tax effects of temporary differences and related deferred tax assets and liabilities as of December 31, 2015 and 2014 were as follows:

	December 31,
	2015		2014
Deferred tax assets:
Depreciation and other	$	—	$	1,409
Net operating loss carryforwards		26,826		19,525
Unused R& D tax credits		530		381
Accruals & reserves		317		—
Deferred Revenue		693		—
Stock Compensation		1,222		—
Other		43		—
Deferred tax liabilities:
Depreciation and other		(220)		—
Prepaid expenses		(113)		—
Less: Valuation allowance		(29,298)		(21,315)
Net deferred tax asset (liability)	$	—	$	—

The Company’s accounting for deferred taxes involves the evaluation of a number of factors concerning the realizability of the Company’s net deferred tax assets. The Company primarily considered such factors as the Company’s history of operating losses; the nature of the Company’s deferred tax assets and the timing, likelihood and amount, if any, of future taxable income during the periods in which those temporary differences and carryforwards become deductible. At present, the Company does not believe that it is more likely than not that the deferred tax assets will be realized; accordingly, a full valuation allowance was established and no deferred tax assets were shown in the accompanying balance sheets. The valuation allowance increased by $7,983, and $6,371 during the years ended December 31, 2015 and 2014, respectively.

As of December 31, 2015 the Company had federal net operating loss carryforwards of $71,901. The Company also had federal research and development tax credit carryforwards of $534. The net operating loss and tax credit carryforwards will expire at various dates beginning in 2027, if not utilized.

As of December 31, 2015, the Company had state net operating loss carryforwards of $56,894, which will begin to expire in 2017. The Company also had state research and development tax credit carryforwards of $260, which have no expiration.

As of December 31, 2015, $1,662 of federal and $767 of state net operating loss is attributable to stock-based compensation deductions in excess of book expense. When realized, the benefit of the tax deduction related to these options will be accounted for as a credit to stockholders’ equity rather than as a reduction of the income tax provision.

Utilization of the Company’s net operating losses and credit carryforwards may be subject to annual limitations in the event of a Section 382 ownership change. Such future limitations could result in the expiration of net operating losses and credit carryforwards before utilization as a result of such an ownership change.

A reconciliation of the beginning and ending amount of unrecognized tax benefits were as follows:

Balance at December 31, 2013	$	93
Increase of unrecognized tax benefits taken in prior years		4
Increase of unrecognized tax benefits related to current year		46
Balance at December 31, 2014	$	143
Decrease of unrecognized tax benefits taken in prior years		(19)
Increase of unrecognized tax benefits related to current year		75
Balance at December 31, 2015	$	199
Balance at December 31, 2015	$	199

If the Company eventually is able to recognize these uncertain tax positions, the unrecognized tax benefits would not reduce the effective tax rate if the Company is applying a full valuation allowance against the deferred tax assets, as is the Company’s current policy.

The Company had not incurred any material tax interest or penalties as of December 31, 2015. The Company does not anticipate any significant change within 12 months of this reporting date of its uncertain tax positions. The Company is subject to taxation in the United States, the United Kingdom, Germany and various states jurisdictions. There are no other ongoing examinations by taxing authorities at this time. The Company’s tax years 2007 through 2015 will remain open for examination by the federal and state authorities for three and four years, respectively, from the date of utilization of any net operating loss credits.